SLC5A1 and colonic neoplasm: SwissTarget Prediction and TargetNet forecast indicate that SLC5A1 is the only target with a binding probability exceeding 0.05, consistently identified in both databases, exhibiting expression changes in colon cancer cells treated with Hesperidin.